Sd Biosensor, Inc.
Manufacturer and developer of in vitro diagnostic devices and assays focused on rapid diagnostic tests (lateral-flow), fluorescence immunoassay analyzers, ELISA systems, point-of-care molecular diagnostics, interferon-gamma release assays (IGRA) and blood glucose monitoring devices. Engages in technology transfer and licensing to expand manufacturing access for infectious-disease diagnostics and participates in industry and investor events.
Industries
Nr. of Employees
large (251-1000)
Sd Biosensor, Inc.
Suwon, Ch'ungch'ong-namdo, South Korea, Asia
Patents
Genome extraction device including safety clip combined with inner chamber
US-12303885-B2
View DetailsGenome extraction device of dual chamber structure in which outer chamber and inner chamber are combined with each other
US-12239979-B2
View DetailsGenome extraction device of dual chamber structure in which outer chamber and bead chamber are combined with each other
US-11938478-B2
View DetailsIsothermal based-dual functional oligonucleotide including reporter dye, and quencher for isothermal nucleic acid amplification and measurement methods using
US-11795514-B2
View Details
Genome extraction device including safety clip combined with inner chamber
US-12303885-B2
View DetailsGenome extraction device of dual chamber structure in which outer chamber and inner chamber are combined with each other
US-12239979-B2
View DetailsGenome extraction device of dual chamber structure in which outer chamber and bead chamber are combined with each other
US-11938478-B2
View DetailsIsothermal based-dual functional oligonucleotide including reporter dye, and quencher for isothermal nucleic acid amplification and measurement methods using
US-11795514-B2
View DetailsProducts
STANDARD Q
Rapid lateral-flow diagnostic tests with quality control processes from raw material development to production; used for a range of rapid test parameters.
STANDARD F
Multi-parametric, random-access fluorescence immunoassay (FIA) analyzer for laboratory diagnostics.
STANDARD E
Enzyme-linked immunosorbent assay (ELISA) system intended for accurate mass screening tests.
STANDARD M
Point-of-care molecular diagnostic (MDx) system intended to deliver molecular test results near the patient for faster clinical decision-making.
Procell DX
In vitro diagnostic products including assays for infectious diseases (e.g., tuberculosis, SARS-CoV-2) and interferon-gamma release assays for immune-status assessment.
BGMS
Blood glucose meters for self-monitoring of blood glucose with associated consumables.
STANDARD Q
Rapid lateral-flow diagnostic tests with quality control processes from raw material development to production; used for a range of rapid test parameters.
STANDARD F
Multi-parametric, random-access fluorescence immunoassay (FIA) analyzer for laboratory diagnostics.
STANDARD E
Enzyme-linked immunosorbent assay (ELISA) system intended for accurate mass screening tests.
STANDARD M
Point-of-care molecular diagnostic (MDx) system intended to deliver molecular test results near the patient for faster clinical decision-making.
Procell DX
In vitro diagnostic products including assays for infectious diseases (e.g., tuberculosis, SARS-CoV-2) and interferon-gamma release assays for immune-status assessment.
BGMS
Blood glucose meters for self-monitoring of blood glucose with associated consumables.
Expertise Areas
- Rapid diagnostic test development
- Point-of-care molecular diagnostics
- Immunoassay development (ELISA, FIA)
- Infectious disease diagnostics
Key Technologies
- Lateral flow immunoassays
- Fluorescence immunoassay (FIA)
- Enzyme-linked immunosorbent assay (ELISA)
- Point-of-care molecular diagnostics (MDx)
News & Updates
Participation in IAS 2025 (conference presence and exhibition activities).
Participation in the TECA 2025 event.
A license agreement with the WHO and the Medicines Patent Pool to provide sublicensees with rights, know-how and material to manufacture rapid diagnostic testing technology for COVID-19 and other diseases.
Company presentation at the JP Morgan Healthcare Conference (APAC & LATAM section).
Announcement of a US$21 million investment to bring molecular diagnostic testing for COVID-19 and other infectious diseases closer to patients in low- and middle-income countries.
Participation in IAS 2025 (conference presence and exhibition activities).
Participation in the TECA 2025 event.
A license agreement with the WHO and the Medicines Patent Pool to provide sublicensees with rights, know-how and material to manufacture rapid diagnostic testing technology for COVID-19 and other diseases.
Company presentation at the JP Morgan Healthcare Conference (APAC & LATAM section).
Announcement of a US$21 million investment to bring molecular diagnostic testing for COVID-19 and other infectious diseases closer to patients in low- and middle-income countries.